Improving Percentage of Successful Bowel Cleansing among Patients Prescribed with Polyethylene-Glycol (PEG)-4000 Powder for Colonoscopy in Hospital Tuanku Ja'afar Seremban (HTJS)

ADIBAH BINTI MURAYADI

PEGAWAI FARMASI UF52 HOSPITAL TUANKU JA'AFAR SEREMBAN NEGERI SEMBILAN





TEAM MEMBERS

Pharmacy Dept.


Ahmad Ridza bin Ahmad Nizam Cheong Jia Wen Siti Nabilah binti Md Yazid Tien Ja She Adibah binti Murayadi Muhammad Sahmi bin Mohd Sairi Shirlie Goh Thanapriya Anbalagan

A collaboration between Pharmacy Dept. & Surgical Dept. HTJS



Surgical Dept.


Dr (Mdm) Zaidah binti Mohd Ali Dr (Ms) Norfarizan binti Azmi Abdul Aziz bin Ab Mulup Shamsul Akman bin Anuar Fazliana binti Mokhtar




SELECTION OF OPPORTUNITY FOR IMPROVEMENT **Problem** Identification 1. Formulate Study Objectives **Problem Prioritizations Effect of Change** 2. Measure Quality 2.1 Identify Indicator **QA/QI CYCLE** 2.2 Identify Variables The Problem Solving 2.2 Identify Criteria Approach **Implementation Problem Analysis** of Remedial Measures 2.2 Set Standard 3. Review Process of Care 4. Develop MOGC Gathering **Identification of** Information and **Strategy Analysis** 5. Plan of Data Collection 6. Plan for Data Analysis



PROBLEM IDENTIFICATION





Powder

Low percentage
of proper
handling on liquid
preparation

Long waiting time for prescription with psychotropics in Outpatient Pharmacy

PRIORITIZATION OF PROBLEM

QUALITY ISSUE	S	M	A	R	Т	Total
Low percentage of correct tube use for TDM blood sample	18	14	22	28	38	120
Low percentage of successful bowel cleansing for colonoscopy among patients prescribed with Polyethylene-Glycol (PEG)-4000 Powder	36	38	35	38	37	184
Long waiting time for prescription with psychotropics in Outpatient Pharmacy	28	34	33	26	33	154
Low percentage of proper handling on liquid preparation	22	14	34	30	15	115

Rating Scale 1=Low, 2=Medium, 3=High

SMART Criteria

13 Group Members



REFINED TITLE

Low Percentage

of Successful Bowel
Cleansing for
Colonoscopy among
Patients Prescribed
with PolyethyleneGlycol (PEG)-4000
Powder



Improving Percentage

of Successful Bowel Cleansing among Patients Prescribed with Polyethylene-Glycol (PEG)-4000 Powder for Colonoscopy in Hospital Tuanku Ja'afar Seremban (HTJS)

REASONS FOR SELECTION



REASONS FOR SELECTION (SERIOUSNESS) Increased Healthcare Cost^{1,2} Missed Lesion and Reduced Colorectal Decrease Colonoscopy **Cancer Detection** Effectiveness² Rate^{2,3} Unsuccessful **Bowel Cleansing** Delayed Diagnosis and for Colonoscopy Treatment of Colorectal Cancer, may lead to **Unnecessary Repeated** Mortality^{2,3} Colonoscopy^{1,2} Complications of Repeated Colonoscopy¹ European Society of Gastrointestinal Endoscopy (ESGE) Guideline, 2019 Rex et al. Quality indicators for colonoscopy. Am J Gastroenterol. (2015) 110:72-90. 10.1038 Lebwohl et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc 2011; 73: 1207–14.



Sánchez et al. Prevalence of missed lesions in patients with inadequate bowel preparation through a very early repeat colonoscopy. Dig Endosc 2022; 34: 1176–84.

COLORECTAL CANCER FACTS

Mortality due to colorectal cancer as high as 52% in

2nd most common

Low percentage of successful bowel cleansing for colonoscopy may become an obstacle to achieve National Strategic Plan for Colorectal Cancer 2021-2025 aim for early detection and diagnosis of colorectal cancer in Malaysia

MOST COMMON CANCER

Population	Num	ber
Asia	461	422
Europe	242	483
North America	64	121
*Latin America and the Carribean	64	666
Africa	40	034
Oceania	8	066
Total		792

National Strategic Plan for Colorectal Cancer 2021-2025: to control the colorectal cancer burden in Malaysia by **improving early**detection and diagnosis⁴

- 1. Colorectal cancer facts World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
- 2. E. Goodarzi et al., Worldwide Incidence and Mortality of Colorectal Cancel and Human Development Index (HDI): An Ecological Study. World Cancer Research Journal 2019:6:e1433
- 3. Malaysia National Cancer Registry report: 2012-2016.

WORLDWIDF¹

4. National Strategic Plan for Colorectal Cancer 2021-2025, Ministry of Health, Malaysia



REASONS FOR SELECTION



REASONS FOR SELECTION









Measurable

Percentage of successful bowel cleansing

Appropriateness

Patient care, cost related to patient therapy

Remedieable


Multidisciplinary approach

Timeliness


Estimated to be completed within 1 year



INTRODUCTION



COLONOSCOPY






An endoscopy examination of the colons¹

Gold standard for the detection of polyps and colorectal cancer¹

The ability to detect the colorectal cancer strongly depends on the **quality of bowel cleansing**, which facilitates the clear visualization of the mucosal surface¹

1. National Strategic Plan for Colorectal Cancer 2021-2-25, Ministry of Health, Malaysia





Bowel cleansing procedure



© Mechanisms in Medicine Inc. www.YouAndColonoscopy.com

- A procedure undertaken before a diagnostic
- procedure of the bowel for examining abnormalities and disease¹
- Cleansing of intestines from fecal matter and secretions²
- Involving **laxative medications** and diet modifications²







Hassan et al. 2019. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019. Endoscopy, 51(8), 775–794.

Colonoscopy bowel preparation. Available from: https://my.clevelandclinic.org/health/treatments/22657-colonoscopy-bowel-preparation





Score 0: Poor Presence of liquid or solid faecal content, reventing visualisation Score 1: Regular Presence of liquid or emi-solid faecal content allowing only partial isualisation of mucosa Score 2: Good Scarce liquid faecal content, allowing good visualisation Score 3: Excellent Absence of liquid faecal content, allowing excellent visualisation of mucosa Note: Each segment receives a score of 0-3 according to the amount of remains present and the proportion of evaluable mucosa, and these are added up to produce a total score



Boston Bowel Preparation Scale (BBPS)

- Standardized 9-point assessment scale for the colon
- Colon is divided into 3 segments: right colon, transverse colon, and left colon.
- Each of the segment is classified from **0 to 3** depending on the degree of soiling.
- Sum total of the 3 segments represents the degree of solling scores:

≤5 points: poor bowel cleansing

6-7 points: good bowel cleansing

≥ 8 points: very good bowel cleansing

1.Boston Bowel Preparation Scale. Available from: https://www.endoscopy-campus.com/en/classifications/boston-bowel-preparation-scale/



LITERATURE REVIEW

Only 29% meet the minimum standard of at least 90% colonoscopies with adequate bowel cleansing¹

30.1% patients had poor bowel cleansing in Malaysian tertiary center²









Factors: Long colonoscopy appointment waiting time, non-adherence to bowel cleansing instructions, and incomplete intake of the preparation³

Intensive patient educational programme: counselling, written instructions and educational booklets significantly improve the quality of bowel cleansing for colonoscopy^{4,5}

Janahiraman et al 2020. Effect of an intensive patient educational programme on the quality of bowel preparation for colonoscopy: A single-blind randomised controlled trial. BMJ Open Gastroenterology, 7(1), e000376



^{1.} Maida M, Annibale B, Benedetti A, Burra P, Frulloni L, Ianiro G, Luzza F, Repici A, Savarino E, Sinagra E, Vecchi M, Ricciardiello L Italian Society of Gastroenterology (SIGE) Quality of endoscopic screening for colorectal cancer in Italy: A national survey. Dig Liver Dis. 2022;54:1410–1418.

^{2.} Leong PY, Wong LW. Use of drugs for bowel preparation for colonoscopy in Miri General Hospital. Sarawak Journal of Pharmacy 1 (2018) 84-95

[.] Hautefeuille G, Lapuelle J, Chaussade S, Ponchon T, Molard BR, Coulom P, Laugier R, Henri F, Cadiot G. Factors related to bowel cleansing failure before colonoscopy: Results of the PACOME study. United European Gastroenterol J. 2014 Feb;2(1):22-9.

^{4.} Gkolfakis et al 2019. Strategies to Improve Inpatients' Quality of Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2019, e5147208

PROBLEM STATEMENT

PROBLEM

A study conducted in HTJS (May-June 2022) found only 38.8% successful bowel cleansing among patients prescribed with PEG-4000 powder for colonoscopy in HTJS.

EFFECT

May reduce
cancer detection
rates, miss
diagnosis, and
delay treatment,
besides
increasing costs
and
complications
related to
repeated
colonoscopies.

POSSIBLE CAUSES


Non-compliance
to PEG-4000
powder
instructions, noncompliance to
diet restrictions,
patient forgot to
consume PEG4000, and
unstandardized
bowel cleansing
counselling

AIM OF STUDY

We aim to
improve the
percentage of
successful bowel
cleansing among
patients
prescribed with
PEG-4000 powder
for colonoscopy in
HTJS



PROBLEM ANALYSIS CHART





STUDY OBJECTIVE

General Objective

To improve the percentage of successful bowel cleansing for colonoscopy among patients prescribed with Polyethylene-Glycol (PEG)-4000 powder in HTJS

Specific Objectives

To verify the magnitude of successful bowel cleansing among patients prescribed with PEG-4000 powder for colonoscopy

To determine the probable causes contributing to unsuccessful bowel cleansing for colonoscopy

To formulate medical measures and implement them

To re-evaluate the effectiveness of the remedial measures.



Problem Identification **Problem Prioritizations Effect of Change QA/QI CYCLE** The Problem Solving Approach **Implementation Problem Analysis** of Remedial Measures Gathering **Identification of** Information and **Strategy Analysis**

KEY MEASURES FOR IMPROVEMENT


1. Formulate Study Objectives 2. Measure Quality 2.1 Identify Indicator 2.2 Identify Variables 2.2 Identify Criteria 2.2 Set Standard 3. Review Process of Care 4. Develop MOGC 5. Plan of Data Collection 6. Plan for Data Analysis

PROCESS OF CARE

Pharmacy



Surgical
Outpatient
Clinic / Ward



Plan Patient for Colonoscopy

Prescribe bowel cleansing agent for colonoscopy

Set colonoscopy appointment

Process of Care Surgical Outpatient Clinic / Ward



Screening prescription

Transcribing prescription in PHIS

Filling bowel cleansing agent prescription

Labelling bowel cleansing agent

Dispensing bowel cleansing agent to patient

Counselling patient on proper bowel cleansing procedure

Process of Care Pharmacy





MODEL OF GOOD CARE (MOGC) SURGICAL OUTPATIENT CLINIC/WARD

	STEP	CRITERIA	STANDARD
1.	Plan patient for colonoscopy	 Identify patient indicated for colonoscopy Provide patient with information about colonoscopy and bowel cleansing for colonoscopy Obtain patient's agreement for colonoscopy 	100% 100% 100%
2.	Prescribe bowel cleansing agent for colonoscopy	 Prescribe the appropriate choice of bowel cleansing agent Ensure complete prescription details as below: Correct patient Correct bowel cleansing agent Correct dose Correct frequency Correct date and dosing time for bowel cleansing Correct date and time for colonoscopy Prescriber's sign and stamp Provide patient with bowel cleansing agent product information 	100% 100% 100% 100% 100% 100% 100% 100%
3.	Set colonoscopy appointment date	Provide patient with the date and time details of the scheduled colonoscopy	100%



MODEL OF GOOD CARE (MOGC) PHARMACY (1)

	STEP	CRITERIA	STANDARD
1.	Screening	Ensure prescription is valid	100%
	prescription	Ensure complete prescription details as below: - Correct patient - Correct bowel cleansing agent - Correct dose - Correct frequency - Correct date and dosing time for bowel cleansing - Correct date and time for colonoscopy - Prescriber's sign and stamp	100% 100% 100% 100% 100% 100%
		Provide serial number for identification	100%
2.	Transcribing	Contact prescriber for prescription deemed for pharmacist's intervention	100%
	prescription in PhIS	Transcribe correct patient, correct bowel cleansing agent, correct dose, correct frequency in PhIS system	100%
		Print label for the correct patient from the PhIS system	100%
3.	Filling bowel	Fill according to correct patient, dose, frequency	100%
X	cleansing agent prescription	Fill Polyethylene-Glycol (PEG)-4000 Powder into a designated pouch	100%

MODEL OF GOOD CARE (MOGC) PHARMACY (2)

	STEP	CRITERIA	STANDARD
4.	Labeling bowel cleansing agent	Label according to correct patient, dose, frequency	100%
×		Label date and time for bowel cleansing, date and time for colonoscopy for Polyethylene-Glycol (PEG)-4000 Powder on the designated pouch	100%
5.	Dispensing bowel	Obtain serial number from patient for identification	100%
	cleansing agent to patient	Countercheck to ensure correct patient, correct bowel cleansing agent, correct dose, correct frequency, date and time for bowel cleansing, date and time for colonoscopy	100%
		Dispense Polyethylene-Glycol (PEG)-4000 Powder at a specifically assigned counter	100%
	Counsel patient on bowel cleansing	Provide structural counselling on indication of bowel cleansing, diet restriction, how to consume bowel cleansing agent, date and time for bowel cleansing, date and time for colonoscopy	100%
	instructions	Counselled on how to take Polyethylene-Glycol (PEG)-4000 Powder using the designated pouch	100%
		Counsel patient prescribed with Polyethylene-Glycol (PEG)-4000 Powder on bowel cleansing instructions using comprehensive counselling video	100%

INDICATOR & STANDARD

colonoscopy, a same-day bowel preparation as an accept- ESGE recommends the use of high volume or low volume PEG-based regimens as well as that of non-PEG-based

Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019



tions Assessment, Development, and Evaluation (GRADE) system was adopted to define the strength of recommenches were performed (at least) on Medline (via PubMed) and the Cochrane Central Register of Controlled Trials from after 2013 (date of the previous ESGE guideline [14]) up to Decem-

lonoscopy cost-ineffective [12]. For these reasons, a ≥90% minimum standard for adequate bowel preparation (assessed using validated scales) has been recently recommended by the Quality Committee of the European Society of Gastrointestinal Endoscopy (ESGE) [13].

predictors for cecal intubation failure [4-6] and unsatisfactory held in January 2019 in Munich. Further details on the develop patient experience [7]. In addition it results in shorter colonos- ment methodology of ESGE guidelines have been reported elsecopy surveillance intervals [8,9], longer hospital stays, and in- where [16]. In March 2019, a draft prepared by the task force creased healthcare costs [10, 11] and may render screening colonoscopy cost-ineffective [12]. For these reasons, a ≥90% minimum standard for adequate bowel preparation (assessed using validated scales) has been recently recommended by the Quality Committee of the European Society of Gastrointestinal Endoscopy (ESGE) [13].

Since the publication of the ESGE Guideline on bowel preparation in 2013 [14], additional evidence has been published on the efficacy and safety of different aspects of bowel preparation, including diet, timing, and type of laxative, as well as patient information and specific scenarios. The main aim of this update is to incorporate such new evidence into the clinical recommendations to be adopted in routine and specific

leaders was sent to all group members. After the agreement of

ARRPEVIATIONS

ADR adenoma detection rate

confidence interval

ESGE European Society of Gastrointestinal Endoscopy

GRADE Grading of Recommendations Assessment. Development, and Evaluation

hazard ratio

inflammatory bowel disease

lower gastrointestinal bleeding MCSP magnesium citrate plus sodium picosulfate

oral sodium phosphate oral sulfate solution

polyethylene glycol

randomized controlled trial

relative risk

Indicator

Percentage of successful bowel cleansing for colonoscopy among patients prescribed with Polyethylene-Glycol (PEG)-4000 powder =

Number of patients prescribed with PEG-4000 powder undergoing colonoscopy with BBPS >5

X 100%

Total number of patients prescribed with PEG-4000 powder undergoing colonoscopy


Standard

≥90%

patients achieving successful bowel cleansing

European Society of Gastrointestinal Endoscopy (ESGE) Guideline, 2019








METHODOLOGY

STUDY SAMPLE

Patients prescribed with PEG-4000 powder for bowel cleansing and scheduled for colonoscopy



SAMPLING METHOD

Convenience Sampling

STUDY DESIGN

A quality improvement study

DATA COLLECTION TECHNIQUE

Patient registry for elective colonoscopy, PhIS drug usage report, patient interview



METHODOLOGY (CONT.)

INCLUSION CRITERIA

All patients scheduled for colonoscopy and prescribed with PEG-4000 powder for bowel cleansing


EXCLUSION CRITERIA

Patients prescribed with combined bowel cleansing agents

Patients with language barrier




METHODOLOGY (CONT.)



DATA COLLECTION PLAN

Variables	Data Collection Tools	Location	Samples
Percentage of successful b	owel cleansing		
BBPS Score	BBPS report	Endoscopy	Patients
	Data collection form	unit	scheduled for colonoscopy
	Patient database		
Factors of unsuccessful bo	wel cleansing		
Patient forgot to consume PEG-4000 powder	Interview question Data collection form	Pharmacy	Patients scheduled for
Non-compliance with diet Restriction			colonoscopy
Non-compliance to PEG- 4000 powder instruction			
Unstandardized bowel cleansing counselling	PEG-4000 powder counselling checklist		Pharmacist
	Data collection form for observation		




BBPS SCORE



DATA COLLECTION PLAN

Variables	Data Collection Tools	Location	Samples
Percentage of successful b	owel cleansing		
BBPS Score	BBPS report	Endoscopy	Patients
	Data Collection Form	unit	scheduled for colonoscopy
	Patient database		
Factors of unsuccessful bo	wel cleansing		
Patient forgot to consume	Interview question	Pharmacy	Patients
PEG-4000 powder	Data Collection Form		scheduled for
Non-compliance with diet Restriction			colonoscopy
Non-compliance to PEG- 4000 powder instruction			
Unstandardized bowel cleansing counselling	PEG-4000 powder counselling checklist		Pharmacist
	Data collection form for observation		



		AHUI PUNCA KEGAGALAN PEI	
ebelum inovasi (N°	Isipadu bancuhan tidak	Tidak patuh makanan	Tidak habis minum
Fortrans	tepat	yang dilarang	Fortrans
ואו ועו אוו אוו	المل الملا الملا	भा भा भा भा	1111

Data collection form / Interview form



DATA COLLECTION PLAN

Variables	Data Collection Tools	Location	Samples
Percentage of successful be	owel cleansing		
BBPS Score	BBPS report	Endoscopy	Patients
	Data collection form	unit	scheduled for colonoscopy
	Patient Database		
Factors of unsuccessful bo	wel cleansing		
Patient forgot to consume PEG-4000 powder	Interview question Data collection form	Pharmacy	Patients scheduled for
Non-compliance with diet Restriction			colonoscopy
Non-compliance to PEG- 4000 powder instruction			
Unstandardized bowel cleansing counselling	PEG-4000 powder counselling checklist		Pharmacist
	Data collection form for observation		

3 24/6/22	Cheng Yo	ou Huat	63	1	1	Fortrans	surveillance post AR	Rectosig	moid ca	Mr Siva			
24/6/22	Mohama		73	1	1	Fortrans	screening	NC		Mr Siva			
20/6/22	Gan Tion		60	2+2+2	8	Fortrans	-	Grade 1	internal hemorrhoid	Mr Vimal, Dr Moh		-	
6 20/6/22		ointi Mohamed Japri	47	1	1	Fortrans	pr bleeding	Abdomir	I mass TRO malignancy	Mr Vimal, Dr Moh	an		
27 20/6/22	Ng Ping i		52	1	1	Fortrans	surveillance colonoscopy	Distal re		Ms Farizan		-	
28 20/8/22 29 24/8/22	Norlaily b Norden b		53 69	2+2+2	6	Fortrans Fortrans	hemorrhoid grade 1 TRO GI malionancy	Small he NC	morrhoid	Ms Hayati Ms Hayati	1	-	
30 13/8/22	Pano Kol		80	3+3+3	9	Fortrans	FOBT +ve. or bleed	Constric	fina siamaid tumour	Ms Jasiah		-	
31 13/8/22	Goh Tian		71	1	1	Fortrans	post lap AR with anastomotic s	Anaston	ic stricture with tiny fistula	Ms Jasiah			
32 22/6/22	Rakijah b		70	1	1	Fortrans	altered bowel habit, loose stool	NC		Ms Jasiah			
33 27/8/22		binti Basirun	62	2+2+2	6	Fortrans		Rectal p	olyp	Ms Jasiah			
34 27/6/22	Liaw Thia	am Choi	65	1	1	Fortrans	surveillance colonoscopy	Unused	coltis	Ms Jasiah		_	
35 20/6/22	Juliah bt.	Abas	48	3	3	Fortrans	surveillance colonoscopy	Incomple	ete colonoscopy		h Acute angulation		
38 1/6/22	Ramlah b		63	1	1	Fortrans	Adhesion in pelvic with sigmoid		flexure polyp	Ms Zarina		-	
37 1/6/22	Talhah bi		69	2+2+2	6	Fortrans	left sided diverticular abscess	Pandive	ticulum	Ms Zarina		-	
38 1/6/22 39 7/6/22		d Akmal in Kassim sam A/L Perumal	30 39	2+2+2	8	Fortrans Fortrans	pr bleed & mucus mixed with fa FOBT +ve	r Kectal u	cer	Ms Zarina Ms Zarina			
40 14/8/22	$\overline{}$	t Sin@Wong Fah Sin	78	2	2	Fortrans	altered bowel habit	Sigmoid	diverticulum TRO Malionar	Ms Zarina Ms Zarina			
41 15/8/22	Savarimu	thu AL Retnasamy	73	2+2+2	8	Fortrans	surveillance colonoscoov	Mild red	al polyp TRO malignancy	Ms Zarina			
42 7/6/22	Chong C	hing Yew	85	3+3+3	9	Fortrans	anemia for investigation	Colonic	oolyp	Ms Zawani			
43 7/6/22		bt Shamsudin	71	3+3+3	9	Fortrans	iFOBT +ve	right col	on diverticular disease	Ms Zawani			
44 7/6/22		L G S Paramasivam	66	3+3+3	9	Fortrans	constipation for 20 years, occa-	Rectal p	olyp with hemorrhoid grade	Ms Zawani			
45 21/8/22	Noorain b		38	3+3+3	9	Fortrans	pr bleed secondary to hemorrh	Internal	nemorrhoid	Ms Zawani			
48 21/8/22 47 28/8/22		bt Wahab t Mohamed Yusof	61 50	3+3+2 3+3+3	8	Fortrans Fortrans	iFOBT +ve iFOBT +ve		nemorrhoid oid grade 1	Ms Zawani Ms Zawani			
48 15/8/22		ah A/P Ponnaya	67	3+3+3	9	Fortrans	hx of admission for colitis	NC	oro grade 1	Ms Zawani, Dr M	shan		
49 15/6/22		lukri bin Ramli	67	2	2	Fortrans	perianal swelling	Colitis		Ms Zawani, Syak			
				ts with score >5 =	19								
			- and p	atients = 49 sessful bowel pre	0 = 10/40 -	38.8%							
			70 5000	ressiui nomei pre	p - 18148 =	30.070							
	20	18/1/2023	VAI	Successful	M M	N SH #87	U		60100805	5/IXT			
	77.54					IN DUAKI	r			of the latest and the	8)	
	27	7/2/2023	LIM	NYOK	LAN				43040505	5078	g)	
	28	3/2/2022	MA	CHITAL	RINT	I MOH	AMAD SUHAIN	IV	94101205	5362	8	2	
	77.7						AIVIAD SUNAIIV	11					
	29	3/2/2023	ABE	LATIF	BIN N	TAMAN			51091706	5085	2)	
	30	31/1/2023	ТН	MISIM	VIIE	N			59091810	6187	2		
	30	31/1/2023	1111	IN DOIN	IUE	N .		-	22021010	010/	2		
			100	78 18	19950	111111111	1831 201 5		3 2		20 22		
			Jun	nlah pes	akit	yang me	enjalani kolono	sko	oi mendapa	t BBPS >	5 = 26		
							2						
			Jun	niah pes	akit	yang me	enjalani kolono	SKO	01=30				
						Andrew Comments	an entrance and the same						
			% P	esakit v	ang	perjaya	pembersihan u	ISUS	= 26/30 = 8	6.7%			
				- 1	0	, , ,			7				
			D:	longo		ببغنيلهم	ong nordu n	200	عيامه وزاد	ممحماد	Lani- 1	120-1	3.3%
		4											2.370
						\Box	tient		حا د 4 د				




DATA COLLECTION PLAN

Variables	Data Collection Tools	Location	Samples				
Percentage of successful bowel cleansing							
BBPS Score	BBPS report	Endoscopy	Patients				
	Data collection form	- unit	scheduled for colonoscopy				
	Patient database						
Factors of unsuccessful bo	wel cleansing						
Patient forgot to consume PEG-4000 powder	Interview question Data collection form	Pharmacy	Patients scheduled for				
Non-compliance with diet Restriction			colonoscopy				
Non-compliance to PEG- 4000 powder instruction							
Unstandardized bowel cleansing counselling	PEG-4000 powder counselling checklist		Pharmacist				
	Data collection form for observation						

Name :			Unit:		
	Please tick (* Please tick (*	nophysiology ') YES for correct instruction or sequence. ') NO for incorrect instruction or sequence.			
			Yes (1)	No (0)	Remarks
	GENERAL				
1.	Check patient's case prescribed.	e note and medication chart for medicine(s)			
2.	Confirm the date & t	ime for colonoscopy	+		
3.	Check expiry date a medication (Know Y	nd follow the 5 Rights of administration of	 		
4.	x-ray of the bowel on It works by producing minutes, however, it effect. Expect frequing	d as part of a bowel cleansing procedure before colonoscopy or before a bowel operation. g bowel motions. It usually works within 30 may take as long as 6 hours to produce the ent liquid stocks.			
	7 DAYS BEFORE F a) Stop taking iro b) Persons taking should discont prescribing pit c) Persons taking	n preparation , antiplatelet agents, e.g. aspirin, ticlopidine, nue them upon a prior consultation with the scician , anticoagulants, e.g. warfarin, should contact their ician and change the drugs to low-molecular-			
	2 days before prod Eat a low residue ar particularly those wi fibre cereals.	tedure Indicate the control of the			
7.	and carbonate b) No solid food a	ducts, red/purple-coloured drink or meal, alcohol d drink should not be taken. wifter lunch. clear water before midnight. Avoid taking food			
8.	On the day of proc	redure er medication except for anti diabetic medication.			
	Clear fluid list				
9.	Water, tea are accepts Carbonates coloured). Fruit flavou Strained fru Do not drin!	FORTRANS			
	Clear soup: Strained los Special precauti	Dilute 1 sachet (3 in total) of FORT This should be drunk within 5-6 ho		h1Lofw	rater (3 L i
10.	Frequent be reach to the Some peop It is advisate before and	To improve the flavour, the solut added.	ion may	be chile	d or lemo
		Dosing time: Early morning procedure: First dose taken at 4 pm, second pm, one day before procedure.	dose at 6	6 pm, an	d third do
		Afternoon (or later) procedure: First dose taken at 6 pm, secon procedure and third dose at 6 am			


Counselling Checklist

ANALYSIS AND INTERPRETATION





VERIFICATION DATA



GOAL

To Improve the Percentage of Successful Bowel Cleansing among Patients Prescribed with PEG-4000 powder for colonoscopy in HTJS

38.8%



90.0%

IDENTIFIED CONTRIBUTING FACTORS

47%

Non-compliance to PEG-4000 powder instructions



27%

Non-compliance to diet restriction



26%

Forgot to consume PEG-4000 powder



70%

Unstandardized bowel cleansing counselling



CONFORMATION TO MODEL OF GOOD CARE (MOGC) SURGICAL OUTPATIENT CLINIC/WARD

	STEP		CRITERIA	STANDARD	VERIFICATION
	1. Plan patient colonoscop		 Identify patient indicated for colonoscopy Provide patient with information about colonoscopy and bowel cleansing for colonoscopy Obtain patient's agreement for colonoscopy 	100% 100% 100%	100% 100% 100%
7	Prescribe to cleansing a for colonos	agent	 Prescribe the appropriate choice of bowel cleansing agent Ensure complete prescription details as below: Correct patient Correct bowel cleansing agent Correct dose Correct frequency Correct date and dosing time for bowel cleansing Correct date and time for colonoscopy 	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%
			Prescriber's sign and stampProvide patient with bowel cleansing agent product information	100% 100%	100% 0%
,	3. Set colonos appointmen	. ,	Provide patient with the date and time details of the scheduled colonoscopy	100%	100%

CONFORMATION TO MODEL OF GOOD CARE (MOGC)


PHARMACY (1)

	STEP	CRITERIA	STANDARD	VERIFICATION
1.	Screening	Ensure prescription is valid	100%	100%
	prescription	Ensure complete prescription details as below: - Correct patient - Correct bowel cleansing agent - Correct dose - Correct frequency - Correct date and dosing time for bowel cleansing - Correct date and time for colonoscopy - Prescriber's sign and stamp	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%
		Provide serial number for identification	100%	100%
2.	Transcribing prescription in	Contact prescriber for prescription deemed for pharmacist's intervention	100%	100%
	PhIS	Transcribe correct patient, correct bowel cleansing agent, correct dose, correct frequency in PhIS system	100%	100%
		Print label for the correct patient from the PhIS system	100%	100%
3.	Filling bowel	Fill according to correct patient, dose, frequency	100%	100%
	cleansing agent prescription	Fill Polyethylene-Glycol (PEG)-4000 Powder into a designated pouch	100%	0%

CONFORMATION TO MODEL OF GOOD CARE (MOGC) PHARMACY (2)


STEP		CRITERIA	STANDARD	VERIFICATION
4.	Labeling bowel	Label according to correct patient, dose, frequency	100%	100%
4	cleansing agent	Label date and time for bowel cleansing, date and time for colonoscopy for Polyethylene-Glycol (PEG)-4000 Powder on the designated pouch	100%	0%
5.	Dispensing bowel	Obtain serial number from patient for identification	100%	100%
	cleansing agent to patient	Countercheck to ensure correct patient, correct bowel cleansing agent, correct dose, correct frequency, date and time for bowel cleansing, date and time for colonoscopy	100%	100%
		Dispense Polyethylene-Glycol (PEG)-4000 Powder at a specifically assigned counter	100%	100%
6.	Counsel patient on bowel cleansing	Provide structural counselling on indication of bowel cleansing, diet restriction, how to consume bowel cleansing agent, date and time for bowel cleansing, date and time for colonoscopy	100%	100%
4	instructions	Counselled on how to take Polyethylene-Glycol (PEG)-4000 Powder using the designated pouch	100%	0%
		Counsel patient prescribed with Polyethylene-Glycol (PEG)-4000 Powder on bowel cleansing instructions using comprehensive counselling video	100%	0%

STRATEGY FOR CHANGE & EFFECT OF CHANGE




REMEDIAL MEASURES


- EZY FORTRANSCOUNSELLINGVIDEO
- INTERACTIVE FOCUS GROUP COUNSELING
- CONTINUOUS PROFESSIONAL EDUCATION (CPE)
- o MEMO



- **O CLEAR2GOPOUCH**
- CLEAR2GO
 COMPREHENSIVE
 COUNSELLING VIDEO
 (COOV)

CLEAR2GO REMINDER SYSTEM (CRES) & CLEAR2GO ALERT DATABASE (CRAD)





AFTER

o Simple counselling video

 Can be accessed through scanning QR code on PEG-4000 powder envelope





- Pharmacists provided scheduled group counselling for patients prescribed with PEG-4000 powder for bowel cleansing
- o Interactive
- More time spent for patients instead of limited time at dispensing counter
- Improved patient's understanding
- To increase patient's awareness





Focus

Continuous Professional Education (CPE)

- For health care providers
- To increase awareness and to standardize practice of the implemented strategy
- To improve knowledge& understanding





Awareness Memo

- Memo was distributed to all departments in HTJS
- To increase the awareness about the implemented strategy




EFFECT OF CHANGE: CYCLE 1









ACHIEVEABLE BENEFIT NON-ACHIEVABLE (ABNA): CYCLE 1







Designated Pouch (CLEAR2GO)



- Round corner for safety
- Strong sealing :prevent leaking accidents
- Made from food grade (BPA free material)
- User friendly



AFTER

Designated Pouch (CLEAR2GO)

(CONT.)

AFTER



- Patient does not have an accurate tool to measure 1L
- Use jug /bottle : risk of spillage, not accurate
- Lack of awareness on the important of taking PEG-4000 powder


Provided straw: Easy to drink from the pouch & avoid nausea

Strong Ziplock opening: EASY
POURING WITHOUT SPILLAGE &
LEAKAGE accidents

CYCLE 2

CALIBRATED marking 1000ML for volume of water required

Clear instruction on administration of PEG-4000 powder



Transparent Stand Pouch for drinking PEG-4000 powder solution

If PEG-4000 powder is diluted less than 1L, a hypertonic solution will be formed, which will lead to poor clearance of the bowel.

- PEG-4000 powder need to be diluted with 1L of water to form an isotonic solution.
- Exert an osmotic effect in the colon and sequesters water to the bowel.
- Increase volume of fecal mass trigger propulsive peristalsis via distension of the colonic wall - soften the feaces & ease defecation.

Designated Pouch (CLEAR2GO)

AFTER




Section of timing of dose to be administered:

REMINDER TOOL to enhance adherence and compliance

CYCLE 2 (CONT.)

Date and time of colonoscopy date



Unclear handwriting of the date and timing of dose to be administered

Water-resistant, glossy and clearly written information labelling sticker

Designated Pouch (CLEAR2GO)

AFTER

When and how to do1,2? Day before procedure | Date: SEDER No dietary restriction 1st dose of Fortrans® pure isotonic solution (encourage low fiber and residue diet) 8:00 pm / 10:00 pm 2nd dose of Fortrans® pure isotonic solution Procedure day | Date: Colonoscopies shall be performed within 6:00 am / 9:00 am 3rd dose of Fortrans® pure isotonic solution 4-6 hours after last intake of fluid Your doctor may advise you to take ONE (1) additional dose of Fortrans® pure isotonic solution. Strictly comply with your doctor's prescription Can I continue to have my food3? 7: 44817/23 Milk product, red meat, fruits, vegetables, Plain porridge, white fish, skinless chicken, white bread, egg, whole-meal bread, oat, cereals, seeds, nuts, potato without skin and clear liquid. coloured beverage. Plain water, strained fruit juices without pulp, tea or coffee (without milk or creamer), clears soup, glucose drinks.

- Lack of visual-aid education material
- Black and white photocopy leaflet
- Unattractive product information

CYCLE 2 (CONT.)

- Information on DO's and DON'Ts with coloured-image icon
- Improve compliance to diet restrictions



CLEAR2GO Comprehensive Counselling Video (COOV)

CYCLE 2

When and how to do1,2? Day before procedure | Date: 1st dose of Fortrans® pure isotonic solution (encourage low fiber and residue diet) 8:00 pm / 10:00 pm 2nd dose of Fortrans® pure isotonic solution Procedure day | Date: 6:00 am / 9:00 am 3rd dose of Fortrans® pure isotonic solution Colonoscopies shall be performed within 4-6 hours after last intake of fluid Your doctor may advise you to take ONE (1) additional dose of Fortrans® pure isotonic solution. Strictly comply with your doctor's prescription. Can I continue to have my food3? Milk product, red meat, fruits, vegetables, Plain porridge, white fish, skinless chicken, white bread, egg whole-meal bread, oat, cereals, seeds, nuts, potato without skin and clear liquid. Plain water, strained fruit juices without pulp, tea or coffee (without

milk or creamer), clears soup, glucose drinks.

CYCLE 2 (CONT.)

CYCLE 1



- Simple counselling video
- Accessible
 through
 scanning QR
 code on PEG4000 powder
 envelope

- Improvised, attractive video
- With 3D-illustration and commercial voice-over
- Accessible by scanning the QR code on CLEAR2GO
- Virtual counselling at any time, any place
- Increase knowledge & understanding of patients











EFFECT OF CHANGE: CYCLE 2





ACHIEVEABLE BENEFIT NON-ACHIEVABLE (ABNA): CYCLE 2






CLEAR2GO REMINDER SYSTEM (CRES)

& CLEAR2GO ALERT

DATABASE (CRAD)



CYCLE 3

CLEAR2GO Reminder System (CRES)

Patient would sign up for CRES

PEG-4000 powder and light diet 48 hours before colonoscopy




WARNA	Indikator	
Red	Hantar SMS (Minggu kolonos	kopi)
Yellow	Kumpul maklumat pesakit sebelum kolonoskopi)	(2 minggu
Green	Selesai	


CLEAR2GO Alert Database (CRAD)


- Colour-coded database highlights patients requiring SMS reminder
- SMS would be sent on weekly basis




EFFECT OF CHANGE: CYCLE 3









38.8%

INCREASE

57.5%

INCREASE


77.5%

INCREASE

86.7%



ACHIEVEABLE BENEFIT NON-ACHIEVABLE (ABNA): CYCLE 3



Fisher's Exact Test - p value < 0.001

Clear2Go * BowelPrep Crosstabulation

Count

		Bowel		
		Good	Poor	Total
Clear2Go	Post	26	4	30
	Pre	18	31	49
Total		44	35	79

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	18.801ª	1	<.001	<.001	<.001
Continuity Correction ^b	16.832	1	<.001		
Likelihood Ratio	20.491	1	<.001	<.001	<.001
Fisher's Exact Test				<.001	<.001
N of Valid Cases	79				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 13.29.

b. Computed only for a 2x2 table

ABNA

38.8%

86.7%

p<0.001

CONTRIBUTING FACTORS PERCENTAGE REDUCTION

26% to 0%

70% to 10%

47% to 0%

Non-compliance to PEG-4000 powder instructions



Non-compliance to diet restriction

27% to 2%




Forgot to consume PEG-4000 powder




Unstandardized bowel cleansing counselling




IMPROVED PROCESS OF CARE



Surgical Outpatient Clinic / Ward





Process of Care Pharmacy

Filling bowel cleansing agent prescription

Labelling bowel cleansing agent


Dispensing bowel cleansing agent to patient

Counselling patient on proper bowel cleansing procedure



USING CLEAR2GO POUCH FOR PEG-4000 POWDER

- USING CLEAR2GO POUCH FOR PEG-4000 POWDER
- CLEAR2GO COMPREHENSIVE COUNSELLING VIDEO
- CRAD & CRES TO REMIND PATIENT



CONFORMATION TO MODEL OF GOOD CARE (MOGC) SURGICAL OUTPATIENT CLINIC/WARD

		STEP	CRITERIA	STANDARD	VERIFICA TION	CYCLE 1	CYCLE 2	CYCLE 3
	1.	Plan patient for colonoscopy	 Identify patient indicated for colonoscopy Provide patient with information about colonoscopy and bowel cleansing for colonoscopy Obtain patient's agreement for colonoscopy 	100% 100% 100%	100% 100% 100%	100% 100% 100%	100% 100% 100%	100% 100% 100%
7	2.	Prescribe bowel cleansing agent for colonoscopy	 Prescribe the appropriate choice of bowel cleansing agent Ensure complete prescription details as below: Correct patient Correct bowel cleansing agent Correct dose Correct frequency Correct date and dosing time for bowel cleansing Correct date and time for colonoscopy Prescriber's sign and stamp Provide patient with bowel cleansing agent product information 	100% 100% 100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100% 100% 0%	100% 100% 100% 100% 100% 100% 100% 69%	100% 100% 100% 100% 100% 100% 100% 87%	100% 100% 100% 100% 100% 100% 100% 100%
	3.	Set colonoscopy appointment date	Provide patient with the date and time details of the scheduled colonoscopy	100%	100%	100%	100%	100%



CONFORMATION TO MODEL OF GOOD CARE (MOGC)


PHARMACY (1)

	STEP	CRITERIA	STANDARD	VERIFIC ATION	CYCLE 1	CYCLE 2	CYCLE 3	
1.	Screening prescription	Ensure prescription is valid	100%	100%	100%	100%	100%	
	procential	Ensure complete prescription details as below: - Correct patient - Correct bowel cleansing agent - Correct dose - Correct frequency - Correct date and dosing time for bowel cleansing - Correct date and time for colonoscopy - Prescriber's sign and stamp	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%	100% 100% 100% 100% 100% 100%	
		Provide serial number for identification	100%	100%	100%	100%	100%	
2.	Transcribing	Contact prescriber for prescription deemed for pharmacist's intervention	100%	100%	100%	100%	100%	
	prescription in PhIS	Transcribe correct patient, correct bowel cleansing agent, correct dose, correct frequency in PhIS system	100%	100%	100%	100%	100%	
		Print label for the correct patient from the PhIS system	100%	100%	100%	100%	100%	
3.	Filling	Fill according to correct patient, dose, frequency	100%	100%	100%	100%	100%	
	bowel cleansing agent prescription	Fill Polyethylene-Glycol (PEG)-4000 Powder into a designated pouch	100%	0%	0%	87%	100%	

CONFORMATION TO MODEL OF GOOD CARE (MOGC) PHARMACY (2)


	STEP	CRITERIA	STANDARD	VERIFIC ATION	CYCLE 1	CYCLE 2	CYCLE 3
4.	Labeling bowel	Label according to correct patient, dose, frequency	100%	100%	100%	100%	100%
\	cleansing agent	Label date and time for bowel cleansing, date and time for colonoscopy for Polyethylene-Glycol (PEG)-4000 Powder on the designated pouch	100%	0%	0%	87%	100%
5.	Dispensing bowel cleansing agent to	Obtain serial number from patient for identification	100%	100%	100%	100%	100%
	patient	Countercheck to ensure correct patient, correct bowel cleansing agent, correct dose, correct frequency, date and time for bowel cleansing, date and time for colonoscopy	100%	100%	100%	100%	100%
		Dispense Polyethylene-Glycol (PEG)-4000 Powder at a specifically assigned counter	100%	100%	100%	100%	100%
6.	Counsel patient on	Provide structural counselling on indication of bowel cleansing, diet restriction, how to consume bowel cleansing agent, date and time for bowel cleansing, date and time for colonoscopy	100%	100%	100%	100%	100%
	cleansing instructions	Counselled on how to take Polyethylene-Glycol (PEG)-4000 Powder using the designated pouch	100%	0%	0%	87%	100%
		Counsel patient prescribed with Polyethylene-Glycol (PEG)-4000 Powder on bowel cleansing instructions using comprehensive counselling video	100%	0%	69%	87%	100%

SUSTAINABILITY OF PROJECT



IMPACT

IMPROVING PERCENTAGE OF SUCCESSFUL BOWEL CLEANSING AMONG PATIENTS PRESCRIBED WITH PEG-4000 POWDER FOR COLONOSCOPY IN HTJS






COST - SAVING

Percentage of Repeated Colonoscopy

Cost of Repeated Colonoscopy



	Cost per patient	Pre (30 patients)	Post (4 patients)
PEG-4000 powder	RM 39.26	RM1,177.80	RM157.04
Colonoscopy	RM 300.00	RM 9,000.00	RM 1,200.00
	Total	RM 10,177.80	RM 1,357.04



PREPARATION TIME - SAVING Saving patient's time to prepare PEG-4000 powder solution **BEFORE AFTER** 900 secs 60 secs **SAVING** -840sec 93.3% p<0.001

IMPROVE KNOWLEDGE





LESSONS LEARNT

MULTIDISCIPLINE
APPROACH and
TEAMWORK

IMPROVE PATIENTS' SATISFACTION

IMPROVING
PERCENTAGE OF
SUCCESSFUL BOWEL
CLEANSING AMONG
PATIENTS PRESCRIBED
WITH PEG-4000
POWDER FOR
COLONOSCOPY IN HTJS

Innovative, PATIENTCENTRED health
education and service
delivery

REDUCED UNNECESSARY REPEATED COLONOSCOPY

Workflow changes & task delegation

Top management support



Expansion to Negeri Sembilan hospitals



HOSPITAL TUANKU JA'AFAR (TUANKU JA'AFAR HOSPITAL) Jalan Rasah 70300 Seremban NEGERI SEMBILAN MALAYSIA



Tel : 06-768 4000 (40 talian / lines) Faks : 06-762 5771 Laman Web : www.htjs.moh.gov.my

Ruj. Kami Tarikh

: JF/HTJS/ 1/4 Bil. (67 : 9 Mei 2023

SENARAI EDARAN

(Seperti di Lampiran A)

Tuan/Puan,

MESYUARAT JAWATANKUASA PROJEK KOLABORASI QA/PENYELIDIKAN KLUSTER-2

Adalah saya dengan segala hormatnya merujuk kepada perkara di atas.

Adalah dimaklumkan bahawa mesyuarat di atas akan diadakan pada ketetapan seperti berikut:

kh

29 Mei 2023 (Isnin)

Mase

9.00 am - 4.30 pm

Tempat

Bilik Mesyuarat Azalea, Hospital Rembau

- Agenda mesyuarat adalah seperti berikut.
 - 3.1 Kata-kata aluan Pengerusi Mesyuarat
 - 3.2 Perbincangan pemilihan tajuk penyelidikan (R&D) Kluster 2
 - 3.3 Carta Gantt kajian
 - 3.4 Agihan tugas
 - 3.5 Isu-isu lain
- Kerjasama dan perhatian tuan/puan berhubung perkara ini amatlah dihargai dan didahului dengan ucapan terima kasih.

Sekian.

"MALAYSIA MADANI"

"BERKHIDMAT UNTUK NEGARA"

Saya yang menjalankan amanah,

DR, NOOR SARHRER AZMAN BOLINOHD AL!

NO. MPM 1 35499
Throbian Pengarah Pandellan (W)
Hospital Turafus Jaffatta Sarmafoan

(DATO' DR. ZALEHA BINTI MD NOOR, D.B.N.S., D.S.M.)

NO. MPM 30155

Pengaran,

Hospital Tuanku Ja'afar, Seremban

ahmad_ridza@moh.gov.myi resothi_ellengovan@moh.gov.my

606-768 9610





Expansion to Negeri Sembilan hospitals Publication in initiative quality journals for sharing purpose

CLEAR2GO

Siti Nabilah Md Yazid¹*, Siti Rabia'tul 'Adawiyah Nasri¹, Adibah Murayadi¹, Marzirah Ibrahim¹, Tien Ja She¹

1Hospital Tuanku Jaa'far, Seremban

CLEAR2GO

ABSTRAK

Setinggi-tinggi Kesihatan (Far Jabatan Farma dan semua ah artikel ini.

- Johan I
 Tahun :
- Penyer Sembila

KONFLIK K

Projek ini dibi sepenuhnya. C

Pengenalan: CLEAR2GO merupakan Inovasi Produk yang meningkatkan peratus kejayaan pembersihan usus bagi memastikan perkhidmatan penentuan penyakit dan perawatan cekap dan berkualiti. Pembersihan usus merupakan pra-syarat yang menentukan kualiti imej yang dihasilkan oleh prosedur kolonoskopi. Prosedur kolonoskopi pula merupakan sebuah prosedur yang dapat mengesan sebarang keabnormalan di usus besar dan merupakan 'gold standard' untuk saringan kanser kolorektal. Berdasarkan kajian verifikasi di klinik Endoskopi, Hospital Tuanku Ja'afar, Seremban, didapati pesakit yang dipreskrib ubat polymacrogol 4000 (Fortrans®) atas faktor komorbiditi merupakan golongan yang paling kerap gagal proses pembersihan usus dan terpaksa mengulang semula prosedur kolonoskopi. Obiektif: CLEAR2GO dihasilkan untuk memudahkan penyediaan larutan polymacrogol 4000 bagi meningkatkan kejayaan kolonoskopi kali pertama dan menjimatkan kos dengan mengurangkan kekerapan pesakit untuk mengulangi kolonoskopi Kaedah: CLEAR2GO merupakan pouch minuman ubat Fortrans® pertama di Malaysia. Ia dilengkapi tanda aras 1000ml yang telah dikalibrasi dan maklumat lengkap mengenai pembersihan usus. Rekabentuknya boleh berdiri sendiri, dengan paparan maklumat berwarna dan akses kepada video kaunseling interaktif melalui imbasan kod QR. Peringatan tarikh pengambilan ubat diwujudkan bagi meningkatkan kepatuhan pesakit. Keberhasilan: CLEAR2GO berjaya meningkatkan peratus kejayaan prosedur kolonoskopi pada kali pertama dengan peratus pesakit mendapat skor skala pembersihan usus (Boston Score) melebihi 5 meningkat daripada 38% kepada 87%. Ini membantu mejimatkan kos operasi sebanyak 47.9% dengan penjimatan sehingga RM8,820.76 (86.7%). Masa sediaan larutan Fortrans® juga dijimatkan sebanyak 93%. Pengembangan projek: Projek ini sangat berpotensi untuk dikomersialkan ke seluruh Malaysia mahupun pasaran antarabangsa. Kesimpulan: CLEAR2GO merupakan sebuha produk seragam yang membantu meningkatkan kejayaan proses pembersihan usus yang menjadi pra-syarat kejayaan prosedur kolonoskopi.

[249 patah perkataan]

Kata kunci: pembersihan usus, kolonoskopi, kanser kolorektal,



Expansion to Negeri Sembilan hospitals

Publication in initiative quality journals for sharing purpose

Replication by other hospitals in Malaysia





TELEFON: 06-7664 800 FAKS: 06-7648 613 (Am) 06-7638 543 (Pengarah) WEB: http://jknns.moh.gov.my

Ruj. Kami : JKNNS.BPF.100-2/1 (57) Tarikh: 7Ogos 2023

Ketua Jabatan Farmasi, Hospital Tuanku Ampuan Najihah

Ketua Jabatan Farmasi, Hospital Port Dickson

Ketua Jabatan Farmasi, Hospital Tampin

Ketua Jabatan Farmasi, Hospital Jelebu

Ketua Jabatan Farm Ketua Jabatan Farm

Tuan/Puan.

SOKONGAN PERL HOSPITAL NEGERI

Dengan segala hon JF/HTJS 1/16(18) be

- Sukacita dimi Projek Inovasi "CL Ja'afar, CLEAR2GO mengenai persediaa dan pengambilan ub
- Sehubungan fasiliti farmasi hosp disertakan keteranga tuan/puan berminat, Pegawai Farmasi UF

"MALAYSIA MADA

"BERKHIDMAT UN

"FARMASI PROAK

Saya yang menjalar

(EZATUL RAHAYU Timbalan Pengarah b.p. Pengarah Kesih Jabatan Kesihatan N A AHAM/TSC

> ☐ adibah@moh.gov.m ® +606-766 4810/4864

s k Ketua Jabatan F



JABATAN FARMASI HOSPITAL KUALA LUMPUR JALAN PAHANG.

☑Tel : 03-2615 5555 50586 KUALA LUMPUR

> Ruj.Kami: HKL/FAR/98/100-3/5/3 (30) Tarikh : 28 Ogos 2023

YBRS, DR. AZUWANA BT SUPIAN

Ketua Jabatan Farmasi Hospital Tuanku Ja'afar Seremban

YBrs. Dr.,

PERMOHONAN UNTUK REPLIKASI PRODUK INOVATIF 'CLEAR2GO'

Dengan segala hormatnya saya merujuk kepada perkara di atas.

- Jabatan Farmasi Hospital Kuala Lumpur mengucapkan setinggi-tinggi tahniah di atas kejayaan yang telah dicapai dalam pelbagai pertandingan bagi produk yang berinovasi tinggi seperti Clear2Go. Sehubungan dengan itu, pihak kami berminat dan bercadang untuk mereplikasi produk tersebut memandangkan kami juga menjalankan sesi kaunseling bowel preparation di kalangan pesakit yang bakal menjalani prosedur kolonoskopi setiap bulan. Dengan adanya produk ini pastinya memanfaatkan pesakit dan meningkatkan komplians pesakit.
- 3. Justeru itu, pihak kami amat berbesar hati dan berharap permohonan ini mendapat pertimbangan daripada pihak YBrs. Dr. Jika ada sebarang pertanyaan, pihak YBrs. Dr. boleh menghubungi Puan Tay Chan Yen melalui emel di taychanyen@moh.gov.my / nombor telefon 012-3166595

Sekian, terima kasih

"MALAYSIA MADANI"

"BERKHIDMAT UNTUK NEGARA"

Saya yang nanjalankan amanah

(NORAINI BINTI MOHAMAD) RPh. 1689

Timbalan ¥engarah Farmasi Hospital Kuala Lumpur

Emel: taychanven@moh.gov.my/farizan.ag@moh.gov.my
Tel: +603-26155555 (ext: 1182/5144)

PENYAYANG, KERJA BERPASUKAN, DAN PROFESIONALISME



Expansion to Negeri Sembilan hospitals

Publication in initiative quality journals for sharing purpose

Replication by other hospitals in Malaysia

Commercialization of CLEAR2GO through collaboration with Ministry of Science, Technology and Innovation of Malaysia



No. Tel : 06 768 4000 Direcktunkan bahawa Laporon Pengulan Makinal Menerilakan Bahan Produk Inovasi gala perhatian dan kerjasama dari pihak YBrs. Dr dalam hali ini amat dihargai "BERKHIDMAT UNTUK NEGARA" PERTAHANAN NEGARA TANGGUNGJAWAB BERSAMA ISITI HAJAR BINTI ZULKIFLI Bahagian Teknologi Perlindungan dan Boltzkul b.s Ketua Pengarah STRIDE



This is to certify that

POUCH CLEAR2GO UNTUK MENINGKATKAN KEJAYAAN PESAKIT MENJALANI

Is hereby awarded this certificate in recognition of their participation of MySI Akar Umbi organized by Yayasan Inovasi Malaysia





CONCLUSION

GENERAL OBJ	ECTIVE	FINDINGS						
To improve the percentage of successful keep prescribed with PEG-4000 powder for co		Improved from 38.8% to 86.7% and ultimately 90.2% during re-evaluation						
SPECIFIC OBJECTIVES		FINDINGS						
To verify the magnitude of patients with successful bowel cleansing among patients prescribed with PEG-4000 powder for colonoscopy in HTJS	Verification study: 38.8% Cycle 1: 57.5% Cycle 2: 77.5% Cycle 3: 86.7% Re-evaluation phase: 90.2%							
To determine the probable causes contributing to unsuccessful bowel cleansing among patients prescribed with PEG-4000 powder for colonoscopy.	Patient's non-compliance to PEG-4000 powder instructions (47%) Patient's non-compliance to diet restrictions (27%) Patient forgot to consume PEG-4000 powder (26%). 70% pharmacists performed unstandardized bowel cleansing counselling							
To formulate remedial measures and implement them.	Cycle 1: EZY FORTRANS counselling video, interactive focus group counseling, continuous education memo Cycle 2: CLEAR2GO pouch, CLEAR2GO Comprehensive Counseling Video (COOV) Cycle 3: CLEAR2GO Reminder System (CRES) and CLEAR2GO Alert Database (CRAD)							
To re-evaluate the effectiveness of the remedial measures	ABNA gap was narrowed down							

GANTT'S CHART



Research Activities	May 2022	Jun 2022	Jul 2022	Aug 2022	Sep 2022	Oct 2022	Nov 2022	Dec 2022	Jan 2023	Feb 2023	Mar 2023	Apr 2023	May 2023	Jun 2023	July 2023 – Mar 2024
Proposal development															
Verification															
study															
Data															
collection															
Data analysis															
Remedial															
measures															
Evaluation															
Remedial															
measures															
Evaluation															
Remedial															
measures															
Evaluation															
Report Write															
Up															
Re-evaluation															
Report Write															
Up															



REFERENCES

- 1. Hassan, C., East, J., Radaelli, F., Spada, C., Benamouzig, R., Bisschops, R., Bretthauer, M., Dekker, E., Dinis-Ribeiro, M., Ferlitsch, M., Fuccio, L., Awadie, H., Gralnek, I., Jover, R., Kaminski, M. F., Pellisé, M., Triantafyllou, K., Vanella, G., Mangas-Sanjuan, C., Dumonceau, J.-M.. 2019. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline Update 2019. Endoscopy, 51(8), 775–794.
- 2. National Strategic Plan for Colorectal Cancer 2021-2-25, Ministry of Health, Malaysia
- 3. Rex et al. Quality indicators for colonoscopy. Am J Gastroenterol. (2015) 110:72-90. 10.1038
- 4. Amitay, Efrat L., Tobias Niedermaier, Anton Gies, Michael Hoffmeister, and Hermann Brenner. 2021. Risk Factors of Inadequate Bowel Preparation for Screening Colonoscopy. Journal of Clinical Medicine 10, no. 12: 2740.
- 5. Colonoscopy bowel preparation. Available from: https://my.clevelandclinic.org/health/treatments/22657-colonoscopy-bowel-preparation
- 6. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. Gastroenterology 2014; 147:903–24.
- 7. Leong PY, Wong LW. Use of drugs for bowel preparation for colonoscopy in Miri General Hospital. Sarawak Journal of Pharmacy 1 (2018) 84-95
- 8. Hautefeuille et al. Factors related to bowel cleansing failure before colonoscopy: Results of the PACOME study. United European Gastro J 2014, Vol. 2(1) 22–29.
- 9. Azzani et al. 2019. Provider Costs of Treating Colorectal Cancer in Government Hospital of Malaysia. The Malaysian Journal of Medical Sciences: MJMS, 26(1), 73–86.
- 10. Gkolfakis et al 2019. Strategies to Improve Inpatients' Quality of Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice. e5147208.
- 11. Pantaleón Sánchez M, Gimeno García AZ, Bernad Cabredo B et al. Prevalence of missed lesions in patients with inadequate bowel preparation through a very early repeat colonoscopy. Dig Endosc 2022; 34: 1176–84.
- 12. Janahiraman et al 2020. Effect of an intensive patient educational programme on the quality of bowel preparation for colonoscopy: A single-blind randomised controlled trial. BMJ Open Gastroenterology, 7(1), e000376



ACKNOWLEDGEMENT



ACKNOWLEDGEMENT

Health State Director, Negeri Sembilan State Health Department Dato' Dr Harlina binti Abdul Rashid

Deputy Health State Director (Pharmacy), Negeri Sembilan State Health Department
Pn Ezatul Rahayu binti Anuar

Director of Hospital Tuanku Ja'afar Seremban
Dato' Dr Zaleha binti Md Noor

Head of Pharmacy Department, Hospital Tuanku Ja'afar Seremban Dr Azuwana binti Supian

Head of Surgical Department, Hospital Tuanku Ja'afar Seremban Dr (Mdm) Zaidah binti Mohd Ali

Science and Technology Research Institution for Defence (STRIDE)

THANK YOU